Metabolic disposition of 14C-bromfenac in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 8, 1998, Pages 744-752

  Osman, Mohamed ^a   Chandrasekaran, Appavu ^a   Chan, Kelvin ^a   Scatina, Jo Ann ^a   Ermer, James ^a   Cevallos, William ^a   Sisenwine, Samuel F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOACID; BROMFENAC; CARBON 14; CREATININE; GLUCURONIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ANALGESIC AGENT; BENZOPHENONE DERIVATIVE; BROMOBENZENE; GLUCURONIC ACID;

ADULT; ANALGESIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MALE; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POLYMERIZATION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; ADOLESCENT; ANIMAL; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACACA; MASS SPECTROMETRY; METABOLISM; TISSUE DISTRIBUTION; URINE;

ADOLESCENT; ADULT; ANALGESICS; ANIMALS; AREA UNDER CURVE; BENZOPHENONES; BROMOBENZENES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CREATININE; GLUCURONATES; HALF-LIFE; HUMANS; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 0031595324     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04815.x     Document Type: Article

References (17)

1. Wajdula J, Vavra I, Sullivan D, Ermer J, Osman M: Bromfenac. In, Lewis A, Furst D (eds.): Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Uses. Second edition. New York: Marcel Dekker, 1994;267-284.
2. Nolan JC, Osman MS, Cheng LK, Sancilio LF: Bromfenac, a new non-steroidal anti-inflammatory drug: relationship between the anti-inflammatory and analgesic activity and plasma drug levels in rodents. J Pharmacol Exp Ther 1990;254:104-108.
3. McQuay HJ, Carroll D, Frankland T, Harvey M, Moore A: Bromfenac, acetaminophen, and placebo in orthopedic post-operative pain. Clin Pharmacol Ther 1990;47:760-766.
4. Sancilio LF, Nolan JC, Wagner LE, Ward JW: The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 1987;37:513-519.
5. Forbes JA, Edquit IA, Smith FG, Schwartz MK, Beaver WT: Evaluation of bromfenac, aspirin, ibuprofen in post-operative oral surgery pain. Pharmacotherapy 1991;11:64-70.
6. Bostrom AAS, Forbes JA, Addfsson C, Beaver WT, Bell WE: Evaluation of bromfenac and ibuprofen for pain after orthopedic surgery. Pharmacotherapy 1994;14:305-313.
7. Forbes JA, Beaver WT, Jones KF, Edquist IA. Gongloff CM, Smith WK, et al: Analgesic efficacy of bromfenac, ibuprofen, and aspirin in post-operative oral surgery pain. Clin Pharmacol Ther 1992;51:343-352.
8. Carchman SH, Wimship LC, Crown JT, Osman M, Dunning LK, Wright GJ: Dose proportionality and protein binding of bromfenac, a non-narcotic analgesic in healthy male volunteers (abstract). Clin Pharmacol Ther 1988;43:148.
9. Hogger P, Rohdewald P: Pharmacokinetics of bromfenac in healthy subjects after single oral administration of three different doses. Arzneimittelforschung 1993;43:1114-1118.
10. Gumbhir-Shah K, Cevallos WH, Decleene S, Halstenson CE, Korth-Bradley JM: Absolute bioavailability of bromfenac in humans. Ann Pharmacother 1997;31:395-399.
11. Boni JP, Decleene SA, Cevallos, Hicks DR, Korth-Bradley JM: Effects of age and gender on the pharmacokinetics of bromfenac in healthy volunteers. Ann Pharmacother 1997;31:400-405.
12. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM: Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males. J Clin Pharmacol 1997;37: 160-168.
13. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM: Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis, J Rheumatol 1996;23:984-989.
14. Rocci M, Jasko W: LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1993; 16:203-216.
15. Fluck ER, Homon CA, Knowles JA, Ruelius HW: Differential binding of guanabenz and its metabolites to cerebral α2-receptors: the basis for a radioligand assay specific for the drug. Drug Dev Res 1983;3:91-99.
16. Stierlin H, Faigle JW, Sallmann A, Kung W, Richter WJ, Kriemler HP, et al: Biotransformation of diclofenac sodium (Voltaren7) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 1979;9:601-610.
17. Stierlin H, Faigle JW. Biotransformation of diclofenac sodium (Voltaren7) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites in urine and bile. Xenobiotica 1979;9:611-621.